Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-01-22Clinical Trial Update: Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy
This completed clinical trial reports mid-to-long-term outcomes for CML patients who achieved complete cytogenetic response on first-line im…
-
CLINICAL_TRIALS trial_result · 2014-01-13Clinical Trial Update: Ondansetron Versus Aprepitant Plus Ondansetron for Emesis [Phase 2]
Phase 2 trial comparing ondansetron alone versus aprepitant plus ondansetron for prevention of emesis in patients with hematologic diseases,…
-
CLINICAL_TRIALS trial_result · 2014-01-13Clinical Trial Update: Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib
This clinical trial investigates how ABL mutations change over time in patients with chronic myeloid leukemia who failed imatinib and are tr…
-
CLINICAL_TRIALS research · 2014-01-13Clinical Trial Update: Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib [NA]
This clinical trial update describes a study evaluating the safety and feasibility of discontinuing imatinib in adults with chronic myeloid …
-
CLINICAL_TRIALS research · 2014-01-13Clinical Trial Update: Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)
Clinical trial update on the AMICA study examining patterns of ABL mutations in Asian patients with imatinib-resistant chronic myeloid leuke…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-01-13Clinical Trial Update: Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib [Phase 3]
This Phase 3 trial compares nilotinib with imatinib in Philadelphia chromosome-positive chronic myeloid leukemia patients in early chronic p…
-
CLINICAL_TRIALS trial_result · 2014-01-07Clinical Trial Update: Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance [Phase 3]
Phase 3 trial assessing a low-dose combination of nilotinib and imatinib in chronic myeloid leukemia patients with treatment failure, subopt…
-
CLINICAL_TRIALS trial_result · 2014-01-01Clinical Trial Update: A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation [Phase 1]
A Phase 1 pediatric study evaluating a plerixafor-containing regimen as part of a second allogeneic stem cell transplantation has completed.
-
FDA label_change · 2013-12-20FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) from Takeda Pharmaceuticals America, updating the labeling for…
-
CLINICAL_TRIALS research · 2013-12-19Clinical Trial Update: Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia [Phase 3]
Clinical trial update for a Phase 3 study evaluating interferon alfa in newly diagnosed chronic myeloid leukemia; no efficacy results are pr…
-
CLINICAL_TRIALS trial_result · 2013-12-18Clinical Trial Update: PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy [Phase 2]
This is a Phase 2 clinical trial update evaluating PHA-739358 for patients with chronic myeloid leukemia that relapsed after imatinib mesyla…
-
CLINICAL_TRIALS trial_result · 2013-12-18Clinical Trial Update: Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia [Phase 3]
This update describes a Phase 3 clinical trial evaluating chemotherapy and biological therapy with or without bone marrow or peripheral stem…
-
CLINICAL_TRIALS trial_result · 2013-12-10Clinical Trial Update: A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation [Phase 1]
A Phase I study evaluating WT1 peptide immunotherapy to induce anti-leukemia immune responses after transplantation was terminated.
-
EMA guidance · 2013-11-22European Medicines Agency recommends changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise risk of blood clots
EMA recommends changes in how ponatinib (Iclusig) is used to reduce the risk of blood clots in leukemia treatment.
-
EMA safety_alert · 2013-11-08PRAC updates on the risks of serious vascular occlusive events associated with cancer medicine Iclusig
PRAC provides updates on the risk of serious vascular occlusive events with cancer medicine Iclusig (ponatinib), highlighting safety concern…
-
CLINICAL_TRIALS trial_result · 2013-11-06Clinical Trial Update: Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma [Phase 2]
A Phase 2 clinical trial update describes using arsenic trioxide to treat patients with recurrent or refractory acute leukemia, chronic myel…
-
CLINICAL_TRIALS trial_result · 2013-10-16Clinical Trial Update: Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia [Phase 1]
Phase 1 trial update of cladribine, cytarabine, and imatinib mesylate in refractory or relapsed acute myeloid leukemia or blastic phase chro…
-
CLINICAL_TRIALS trial_result · 2013-10-14Clinical Trial Update: Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia [Phase 3]
Phase 3 trial comparing imatinib to interferon-α plus cytarabine in newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemi…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes [Phase 1]
A Phase 1 study evaluating the combination of vorinostat with idarubicin in patients with relapsed or refractory leukemia or myelodysplastic…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes [Phase 1]
Phase 1 trial of the combination therapy 7-Hydroxystaurosporine and perifosine in adults with relapsed or refractory acute leukemias, chroni…
-
FDA label_change · 2013-09-27FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tasigna (nilotinib) from Novartis, outlining changes to the drug’s labeling.
-
CLINICAL_TRIALS trial_result · 2013-09-17Clinical Trial Update: Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia [Phase 1, Phase 2]
This document reports on a Phase 1/2 clinical trial evaluating the combination of Imatinib Mesylate and Cytarabine in newly diagnosed chroni…
-
FDA approval · 2013-08-14FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tasigna (nilotinib) from Novartis Pharmaceuticals Corporation. The approval updates the labeling…
-
CLINICAL_TRIALS trial_result · 2013-08-14Clinical Trial Update: Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies [NA]
This clinical trial update indicates that a pilot study of umbilical cord blood transplantation in adults with advanced hematopoietic malign…
-
CLINICAL_TRIALS trial_result · 2013-08-02Clinical Trial Update: Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia [Phase 3]
Phase 3 clinical trial update evaluating chemotherapy, interferon, and bone marrow transplantation for chronic myeloid leukemia.